Loading...
Loading...
NAMSW| Name | Value |
|---|---|
| Revenues | 97.5M |
| Cost of Revenue | 0.0M |
| Gross Profit | 97.5M |
| Operating Expense | -104.5M |
| Operating I/L | 22.4M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.0M |
| Pretax | 21.4M |
| Income Tax Expense | 1.1M |
| Net Income/Loss | 20.4M |
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company specializing in developing treatments for metabolic diseases. Their lead investigational candidate, obicetrapib, is a selective inhibitor targeting the Cholesteryl Ester Transfer Protein (CETP), which has demonstrated the ability to reduce low-density lipoprotein cholesterol (LDL-C) and increase high-density lipoprotein cholesterol (HDL-C). The company's focus on developing novel therapies for metabolic diseases positions them to generate revenue through the successful development and commercialization of their innovative treatments.
